---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-25-000055"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:26:22.036066+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q3 net loss $19M ($0.21/sh); cash $210.8M; debt facility upsized to $125M

## Summary
- Cash and investments $210.8M, up 60% from Dec 2024; net loss $19.0M vs $22.8M year ago.
- Hercules loan amended to $125M; drew additional $20M at close; interest-only period extended to 30 months.
- Phase 2b IMPACT 48-week MASH data expected before year end; End-of-Phase-2 FDA meeting scheduled Q4 2025.
- RECLAIM AUD trial enrollment completed early; topline results expected in 2026. RESTORE ALD trial initiated.
- Appointed CMO (Dr. Arbet-Engels), CCO (Richardson), and CLO (Abrams) to executive team.

## SEC filing metadata
- accession: 0001326190-25-000055
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/0001326190-25-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/alt-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-25-000055
- JSON: https://secwatch.observer/filing/0001326190-25-000055.json
- Plain text: https://secwatch.observer/filing/0001326190-25-000055.txt

## Key facts
- Debt Financings
  Altimmune, Inc. amended term loan of from an aggregate principal amount of $100.0 million to $125.0 million with Hercules Capital, Inc. at greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall St maturing 30 months from May 13, 2025.
  - Instrument: term loan
  - Principal: from an aggregate principal amount of $100.0 million to $125.0 million
  - Counterparty: Hercules Capital, Inc.
  - Rate: greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall St
  - Maturity: 30 months from May 13, 2025
  - Event: amendment
  source text: Company and Hercules. Under the terms of the Amendment, the lenders will, among other things, increase the availability under the Term Loan from an aggregate principal amount of $100.0 million to $125.0 million. The first Term Loan tranche was drawn down at closing on May 13, 2025 in an aggregate principal amount of $15.0 million. The second Term Loan tranche was drawn
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000055/0001326190-25-000055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.